II期临床-话题@MedSci

#II期临床#

478篇内容 | 2562人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524627, encodeId=1eed152462e6c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=21, createdTime=2017-10-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524626, encodeId=ae2015246267d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM：埃博拉疫苗III期临床研究, objectType=article, longId=115953, objectId=514d11595351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514d11595351, replyNumber=0, likeNumber=53, createdTime=2017-10-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514d11595351, moduleTitle=NEJM：埃博拉疫苗III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514d11595351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524625, encodeId=c9b6152462557, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, objectType=article, longId=113798, objectId=4275113e9856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4275113e9856, replyNumber=0, likeNumber=68, createdTime=2017-09-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4275113e9856, moduleTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4275113e9856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524624, encodeId=30e21524624bb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, objectType=article, longId=107571, objectId=185210e571e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185210e571e9, replyNumber=0, likeNumber=73, createdTime=2017-08-05, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185210e571e9, moduleTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185210e571e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524623, encodeId=650f152462325, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, objectType=article, longId=107035, objectId=461b10e035bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461b10e035bf, replyNumber=0, likeNumber=76, createdTime=2017-07-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461b10e035bf, moduleTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461b10e035bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524622, encodeId=7d9715246222b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, objectType=article, longId=103410, objectId=211c103410c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211c103410c6, replyNumber=0, likeNumber=64, createdTime=2017-06-28, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211c103410c6, moduleTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211c103410c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524621, encodeId=09581524621af, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, objectType=article, longId=102825, objectId=3eb2102825e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb2102825e6, replyNumber=0, likeNumber=24, createdTime=2017-06-23, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb2102825e6, moduleTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb2102825e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524620, encodeId=19af15246203b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, objectType=article, longId=93569, objectId=376693569b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376693569b4, replyNumber=0, likeNumber=23, createdTime=2017-03-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376693569b4, moduleTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376693569b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524619, encodeId=30f71524619ba, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, objectType=article, longId=93796, objectId=066d93e9684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=066d93e9684, replyNumber=0, likeNumber=71, createdTime=2017-03-26, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=066d93e9684, moduleTitle=重大打击！诺华急性心衰药物RLX030关键III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=066d93e9684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524618, encodeId=3539152461889, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求, objectType=article, longId=91934, objectId=84fa919345f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84fa919345f, replyNumber=0, likeNumber=0, createdTime=2017-03-16, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84fa919345f, moduleTitle=安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84fa919345f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524617, encodeId=be82152461ea2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据, objectType=article, longId=88383, objectId=7d0588383e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0588383e4, replyNumber=0, likeNumber=77, createdTime=2017-02-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0588383e4, moduleTitle=辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0588383e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524616, encodeId=501f152461650, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, objectType=article, longId=87131, objectId=d5598e13167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5598e13167, replyNumber=0, likeNumber=72, createdTime=2017-01-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5598e13167, moduleTitle=艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5598e13167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524615, encodeId=d9fc1524615bb, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, objectType=article, longId=85803, objectId=b71585803c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b71585803c3, replyNumber=0, likeNumber=54, createdTime=2016-12-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b71585803c3, moduleTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b71585803c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524614, encodeId=cc54152461432, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, objectType=article, longId=85558, objectId=25048555835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25048555835, replyNumber=0, likeNumber=65, createdTime=2016-12-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25048555835, moduleTitle=辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25048555835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524612, encodeId=49771524612e6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发, objectType=article, longId=79538, objectId=9109e953862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9109e953862, replyNumber=0, likeNumber=57, createdTime=2016-10-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9109e953862, moduleTitle=美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9109e953862)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524613, encodeId=39d615246130a, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, objectType=article, longId=79539, objectId=ef32e9539e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef32e9539e8, replyNumber=0, likeNumber=27, createdTime=2016-10-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef32e9539e8, moduleTitle=卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef32e9539e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524610, encodeId=b8b21524610ad, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知, objectType=article, longId=78706, objectId=3481e870661, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3481e870661, replyNumber=0, likeNumber=57, createdTime=2016-09-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3481e870661, moduleTitle=老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3481e870661)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524611, encodeId=eced152461196, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, objectType=article, longId=78707, objectId=88a4e870731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88a4e870731, replyNumber=0, likeNumber=61, createdTime=2016-09-29, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88a4e870731, moduleTitle=重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88a4e870731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524609, encodeId=a4fa1524609dc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, objectType=article, longId=78308, objectId=7164e8308d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7164e8308d1, replyNumber=0, likeNumber=25, createdTime=2016-09-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7164e8308d1, moduleTitle=EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7164e8308d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524608, encodeId=dcfd15246087b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, objectType=article, longId=77934, objectId=92cfe7934e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cfe7934e2, replyNumber=0, likeNumber=108, createdTime=2016-09-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cfe7934e2, moduleTitle=强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cfe7934e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

2017-10-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM：埃博拉疫苗III期临床研究

2017-10-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

肾性贫血首创药罗沙司他III期临床研究结果发布

2017-09-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究

2017-08-05

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险

2017-07-30

爆笑小医 (审核中...)

前往app查看评论内容

#II期临床#

JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）

2017-06-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）

2017-06-23

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究

2017-03-29

docwu2019 (审核中...)

前往app查看评论内容

#II期临床#

重大打击！诺华急性心衰药物RLX030关键III期临床失败

2017-03-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

安进新一代降脂药Repatha&nbspIII期临床显著降低高胆固醇患者机采需求

2017-03-16

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞艰难梭菌疫苗产品PF-06425090在II期临床收获激动人心数据

2017-02-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

艾伯维香菇蓝瘦！辉瑞阿达木单抗生物仿制药PF-06410293在III期临床获得成功

2017-01-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功

2016-12-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

辉瑞赫赛汀生物仿制药达乳腺癌III期临床试验主要终点

2016-12-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

美国BARDA资助赛诺菲4320万美元资金，推动寨卡（Zika）疫苗进入II期临床开发

2016-10-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌（RCC）进入III期临床开发

2016-10-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

老年性痴呆药物再失败！灵北5-HT6受体拮抗剂idalopirdineIII期临床未改善轻度至中度AD患者认知

2016-09-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

重磅！诺华新型靶向抗癌药Zykadia一线治疗晚期ALK+肺癌III期临床获得成功，辉瑞霸主地位将不保

2016-09-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

EASD 2016：阿斯利康2型糖尿病组合疗法Bydureon/Forxiga（GLP-1RA/SGLT-2i）III期临床显著降低血糖水平、体重、收缩压

2016-09-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

强生危险！辉瑞英夫利昔生物类似药PF-06438179 III期临床获得成功

2016-09-21

科室
- - 订阅+
  - 更多科室
工具
服务